November 04, 2025

Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors

In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall surviva...

The ASCO Post

October 21, 2025

Impact of HER2-Receptor Status in mCRC Treated With Chemotherapy Plus Bevacizumab or Anti-EGFR Agents

In an analysis reported in the Journal of Clinical Oncology, Germani et al identified the impact of HER2 status in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy plus either ...

The ASCO Post

October 21, 2025

Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?

In a Scandinavian trial (ALASCCA) reported in the New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-al...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 02, 2023

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent st...

The ASCO Post

November 13, 2023

FDA Approves Fruquintinib for Refractory Metastatic Colorectal Cancer

On November 8, the FDA approved an anti-VEGF tyrosine kinase inhibitor for adult patients with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based che...

The ASCO Post

June 23, 2023

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Dr. Lisa Newman emphasizes the critical relevance of including diverse populations in clinical genomic profiling for colorectal cancer, shedding light on potential missed opportunities in homogeneous population studies.

The ASCO Post

April 30, 2025

AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash

Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial re...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post